PDCD1 and neoplasm: We underline several possible limitations: (1) a low-immunogenicity tumor model employed; (2) intraperitoneal DCV injection was used (due to close proximity to the tumor and the post-PEF scab) while other injection sites could have been selected; (3) if PD-L1 expression on the DC surface is the reason for lack of synergy, there are two possible ways to improve treatment efficacy—either further optimize the DCV preparation protocol and/or include mAbs that inhibit PD-L1/PD-1 signaling.